REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Formosa Pharmaceuticals, Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Formosa Pharmaceuticals, Inc. Profile Updated: March 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Formosa Pharmaceuticals, Inc. is a biotechnology pharmaceutical company focusing on the treatment fields of Ophthalmology, oncology and anti infective drugs. It is committed to drug development in preclinical and clinical stages.

Headquarters
8F-6, No. 57, Fuxing N. Rd
Taipei City; Taipei City;

Contact Details: Purchase the Formosa Pharmaceuticals, Inc. report to view the information.

Website: http://www.formosapharma.com

Basic Information
Total Employees:
Purchase the Formosa Pharmaceuticals, Inc. report to view the information.
Outstanding Shares:
Purchase the Formosa Pharmaceuticals, Inc. report to view the information.
Financial Auditors:
Purchase the Formosa Pharmaceuticals, Inc. report to view the information.
Incorporation Date:
December 06, 2010
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
45.84%
Purchase this report to view the information.
4.48%
Purchase this report to view the information.
0.4%
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Activus Pharma.Co., Ltd. (Japan)
99.23%
Company Performance
Financial values in the chart are available after Formosa Pharmaceuticals, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
335.07%▲
Total operating revenue
335.15%▲
Operating profit (EBIT)
34.4%▲
EBITDA
42.96%▲
Net Profit (Loss) for the Period
16.85%▲
Total assets
-15.6%▼
Total equity
-25.11%▼
Operating Profit Margin (ROS)
400.15%▲
Net Profit Margin
369.52%▲
Return on Equity (ROE)
-1.14%▼
Quick Ratio
-4.61%▼
Cash Ratio
-8.92%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo